Topical Afimoxifene in Treating Patients with Breast Cancer Who Have Undergone Radiation Therapy on One Breast
- Patients must have received prior unilateral breast radiotherapy (RT) for ductal breast carcinoma in situ (DCIS) or invasive cancer (>= 12 weeks after the end of RT), and have an intact unradiated (non-RT) breast. * Note: The upper limit for interval since RT will be 5 years, since oral endocrine therapy (OET) for DCIS is usually administered during the 5 years that follow the end of RT.
- Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%).
- No history of coagulopathy, or daily use of aspirin/nonsteroidal antiinflammatory drugs (NSAIDs).
- A prior history of malignancy is allowed, as long as the patient is considered to have “no evaluable disease” and cancer treatment has been completed.
- Females of child-bearing potential (FOCBP) and male partners of female participants must agree to use TWO effective forms of birth control (abstinence is not an allowed method) prior to study entry and for the duration of study participation, and for two months following the last dose of study medications. Effective birth control methods are: copper IUD (intrauterine device), diaphragm/cervical cap/shield, spermicide, contraceptive sponge, condoms. Should a female patient become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. * NOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: ** Has not undergone a hysterectomy or bilateral oophorectomy ** Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for > 12 months).
- FOCBP must have a negative urine pregnancy test within 7 days prior to registration on study.
- Willingness to avoid exposing breast skin to natural or artificial sunlight (i.e. tanning beds) for the duration of the study drug use.
- Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study.
- Patients receiving any other investigational agents within 30 days of registration are not eligible.
- Patients currently using oral selective estrogen receptor modulators (SERMS) (tamoxifen, raloxifene, bazedoxifene) are not eligible. * Note: Prior or current endocrine therapy other than SERMs are allowed.
- Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition afimoxifene (4-OHT) are not eligible.
- Patients who have an uncontrolled intercurrent illness including, but not limited to any of the following, are not eligible: * Hypertension that is not controlled on medication * Ongoing or active infection requiring systemic treatment * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia * Psychiatric illness/social situations that would limit compliance with study requirements * Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient’s safety or study endpoints.
- Female patients who are pregnant or nursing are not eligible.
- Patients with prior bilateral breast cancer radiotherapy or radiotherapy for lymphoma will be excluded.
- Patients with skin lesions on the breast that disrupt the stratum corneum (e.g. eczema, ulceration) are not eligible.
- Patients with a history of endometrial neoplasia are not eligible.
- Patients with a history of thromboembolic disease are not eligible. * Note: history of varicose veins and superficial phlebitis is allowed.
- Patients who are undergoing active treatment for any malignancy will be excluded.
- Male patients are excluded from this study since there are no data regarding skin penetration of 4-OHT though male chest wall skin (which is thicker and hairier than female chest wall skin).
I. To identify the skin features that drive inter-individual variation in dermal drug permeation between individuals.
I. To relate breast tissue drug concentration to skin histology, skin vascularity, skin transporter proteins, and skin features measured using confocal reflectance microscopy.
II. To assess the feasibility of transdermal drug delivery to the radiated breast.
Patients apply afimoxifene gel topically once daily (QD) to both breasts for 4 weeks and then undergo core needle biopsies of both breasts.
Patients receive follow up phone call 21-35 days after biopsy.
Trial Phase Phase II
Trial Type Treatment
Seema Ahsan Khan
- Primary ID NU 18B05
- Secondary IDs NCI-2019-03771
- Clinicaltrials.gov ID NCT04009044